<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03277352</url>
  </required_header>
  <id_info>
    <org_study_id>INCAGN 1876-202</org_study_id>
    <nct_id>NCT03277352</nct_id>
  </id_info>
  <brief_title>INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies</brief_title>
  <official_title>A Phase 1/2 Safety and Efficacy Study of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Biosciences International Sàrl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, and efficacy of
      INCAGN01876 when given in combination with immune therapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]</measure>
    <time_frame>Screening through 60 days after end of treatment, up to 18 months</time_frame>
    <description>A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after the first dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months</time_frame>
    <description>Defined as the percentage of subjects having complete response (CR) or partial response (PR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Complete response rate (CRR) based on RECIST v1.1</measure>
    <time_frame>Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months</time_frame>
    <description>Defined as the percentage of checkpoint inhibitor-naive melanoma subjects who have a CR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; Phase 2: ORR based on RECIST v1.1 and mRECIST</measure>
    <time_frame>Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months</time_frame>
    <description>Defined as the percentage of subjects having CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; Phase 2: Disease control rate based on RECIST v1.1 and mRECIST</measure>
    <time_frame>Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months.</time_frame>
    <description>Defined as the percentage of subjects having CR, PR, or stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; Phase 2: Duration of response based on RECIST v1.1 and mRECIST</measure>
    <time_frame>Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months</time_frame>
    <description>Defined as the time from the earliest date of disease response (CR or PR) until earliest date of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; Phase 2: Duration of disease control based on RECIST v1.1 and mRECIST</measure>
    <time_frame>Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months</time_frame>
    <description>Defined as time from first report of SD or better until disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; Phase 2: Progression-free survival based on RECIST v1.1 and mRECIST</measure>
    <time_frame>Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months</time_frame>
    <description>Defined as the time from the start of combination therapy until the earliest date of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; Phase 2: Overall survival</measure>
    <time_frame>At 1 year and 2 years.</time_frame>
    <description>Defined as the time from the start of combination therapy until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 &amp; Phase 2: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]</measure>
    <time_frame>Screening through 60 days after end of treatment, up to 18 months.</time_frame>
    <description>A TEAE is any AE either reported for the first time or worsening of a pre-existing event after the first dose of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Advanced Malignancies</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>INCAGN01876 + Pembrolizumab + Epacadostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCAGN01876 in combination with pembrolizumab and epacadostat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCAGN01876</intervention_name>
    <description>In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose and schedule according to cohort and treatment group enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.</description>
    <arm_group_label>INCAGN01876 + Pembrolizumab + Epacadostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epacadostat</intervention_name>
    <description>Epacadostat will be self-administered orally at the protocol-defined dose.</description>
    <arm_group_label>INCAGN01876 + Pembrolizumab + Epacadostat</arm_group_label>
    <other_name>INCB024360</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be administered IV at the protocol-defined dose.</description>
    <arm_group_label>INCAGN01876 + Pembrolizumab + Epacadostat</arm_group_label>
    <other_name>Keytruda®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced or metastatic disease; locally advanced disease must not be amenable
             to resection with curative intent.

          -  Phase 1: Subjects with advanced or metastatic solid tumors.

          -  Phase 1: Subjects who have disease progression after treatment with available
             therapies.

          -  Phase 2: Subjects with advanced or metastatic melanoma, RCC, and urothelial carcinoma.

          -  Presence of measurable disease based on RECIST v1.1.

          -  Eastern Cooperative Oncology Group performance status of 0 or 1.

        Exclusion Criteria:

          -  Laboratory and medical history parameters not within the Protocol-defined range

          -  Prior treatment with an immune therapy.

          -  Receipt of anticancer medications or investigational drugs within protocol-defined
             intervals before the first administration of study drug.

          -  Has not recovered to ≤ Grade 1 from toxic effects of prior therapy.

          -  Active autoimmune disease.

          -  Known active central nervous system metastases and/or carcinomatous meningitis.

          -  Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.

          -  Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.

          -  Known history of human immunodeficiency virus (HIV; HIV 1/2 antibodies).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin N. Heller, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2017</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>gastric cancer (including stomach and gastroesophageal junction (GEJ))</keyword>
  <keyword>esophageal cancer</keyword>
  <keyword>hepatocellular carcinoma (HCC)</keyword>
  <keyword>melanoma (mucosal or cutaneous)</keyword>
  <keyword>Merkel cell carcinoma</keyword>
  <keyword>mesothelioma</keyword>
  <keyword>microsatellite instability-high (MSI-H)</keyword>
  <keyword>solid tumors</keyword>
  <keyword>non-small cell lung cancer (NSCLC)</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>squamous cell carcinoma of the head and neck (SCCHN)</keyword>
  <keyword>small cell lung cancer (SCLC)</keyword>
  <keyword>renal cell carcinoma (RCC)</keyword>
  <keyword>triple-negative breast cancer (TNBC)</keyword>
  <keyword>urothelial carcinoma</keyword>
  <keyword>glucocorticoid-induced tumor necrosis factor receptor (GITR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

